fda warning letters compounding semaglutide september 2025 Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling FDA unleashes warning letters to

Tirzepatide (Mounjaro/Zepbound) targets both GLP-1 and GIP receptors

For women with under 100 pounds to lose, they likely do not need semaglutide and can lose the weight with diet, hormone, and nutrition changes

Variants in genes like FTO rs9939609 and MC4R rs17782313 can affect how strongly an individual's brain responds to reward signalsa factor that may influence both overeating and nicotine dependence

Semaglutide mimics the GLP-1 hormone in your body that helps reduce hunger by increasing the feeling of fullness

In clinical trials, participants experienced ongoing weight loss for up to 68 weeks

GLP-1-RA-based therapies may help restore mitochondrial function, thereby alleviating pain and promoting neuronal survival